This humanized anti-VEGF antibody specifically binds to VEGF and blocks its interaction with VEGFR [94], hindering VEGF from eliciting its proangiogenic effect and eventually resulting in tumor starvation and growth inhibition. The gene discussed is KDR; the disease is neoplasm.